share_log

Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting

Benzinga ·  Apr 25 19:25
Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment